SVB Securities analyst Joseph Schwartz maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) on July 13. The company’s shares closed last Friday at $1.51, close to its 52-week low of $1.25.
According to TipRanks.com, Schwartz has 0 stars on 0-5 stars ranking scale with an average return of -10.4% and a 35.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $6.17 average price target.
Xeris Pharmaceuticals’ market cap is currently $204.7M and has a P/E ratio of -1.02.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
- SVB Securities Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)
- BioMarin Pharmaceutical (BMRN) Receives a Buy from SVB Securities
- Ascendis Pharma (ASND) Receives a Buy from SVB Securities
- JMP Securities Reaffirms Their Hold Rating on TPG (TPG)
- JMP Securities Maintains Their Hold Rating on Raymond James Financial (RJF)